Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-09-20

Clinical Trial Update: A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing the biosimilar FKB327 to Humira in rheumatoid arthritis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FKB327 (adalimumab biosimilar)
  • Humira (adalimumab)

Snippet

Sponsor: Fujifilm Kyowa Kirin Biologics Co., Ltd. | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2017-09-20